Biology Reference
In-Depth Information
[129] Li H, Kaplan DH, Matte-Martone C, Tan HS, Venkatesan S, Johnson K, et al. Langerhans
cells are not required for graft-versus-host disease. Blood 2011;117(2):697-707.
[130] Chakraverty R, Cote D, Buchli J, Cotter P, Hsu R, Zhao G, et al. An inflammatory check-
point regulates recruitment of graft-versus-host reactive T cells to peripheral tissues.
J Exp Med 2006;203(8):2021-31.
[131] Arpinati M, Chirumbolo G, Urbini B, Perrone G, Rondelli D, Anasetti C. Role of plasma-
cytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem
cell transplantation. Transplant Immunol 2003;11(3-4):345-56.
[132] Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic
cells. Immunity 2008;29(3):352-61.
[133] Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during
viral infections, autoimmunity, and tolerance. Immunol Rev 2010;234(1):142-62.
[134] Tsukamoto H, Chernogorova P, Ayata K, Gerlach UV, Rughani A, Ritchey JW, et al. Defi-
ciency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host disease.
Blood 2012;119(19):4554-64.
[135] Leveson-Gower DB, Olson JA, Sega EI, Luong RH, Baker J, Zeiser R, et al. Low doses
of natural killer T cells provide protection from acute graft-versus-host disease via an
IL-4-dependent mechanism. Blood 2011;117(11):3220-9.
[136] Hoeffel G, Ripoche AC, Matheoud D, Nascimbeni M, Escriou N, Lebon P, et al. Antigen
crosspresentation by human plasmacytoid dendritic cells. Immunity 2007;27(3):
481-92.
[137] Koyama M, Hashimoto D, Aoyama K, Matsuoka K, Karube K, Niiro H, et al. Plasmacy-
toid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as
antigen-presenting cells. Blood 2009;113(9):2088-95.
[138] Banovic T, Markey KA, Kuns RD, Olver SD, Raffelt NC, Don AL, et al. Graft-versus-
host disease prevents the maturation of plasmacytoid dendritic cells. J Immunol
2009;182(2):912-20.
[139] Markey KA, MacDonald KP, Hill GR. Recipient plasmacytoid DCs are not required to
prime allogeneic T-cell responses after BMT. Blood 2009;113(23):6038-9.
[140] Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in
systemic autoimmune disease. Nat Rev Immunol 2001;1(2):147-53.
[141] Ron Y, Sprent J. T cell priming in vivo: a major role for B cells in presenting antigen to T
cells in lymph nodes. J Immunol 1987;138(9):2848-56.
[142] Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells pro-
mote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998;160(1):51-9.
[143] Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with
B cells but lacking serum antibody reveals an antibody-independent role for B cells in
murine lupus. J Exp Med 1999;189(10):1639-48.
[144] Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to
minor histocompatibility antigens and development of graft-versus-host disease. Bone
Marrow Transplant 1995;16(2):289-95.
[145] Rowe V, Banovic T, MacDonald KP, Kuns R, Don AL, Morris ES, et al. Host B cells
produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow
transplantation. Blood 2006;108(7):2485-92.
[146] Matte-Martone C, Wang X, Anderson B, Jain D, Demetris AJ, McNiff J, et al. Recipient B
cells are not required for graft-versus-host disease induction. Biol Blood Marrow Trans-
plant 2010;16(9):1222-30.
[147] Chen W, Gress R, Shlomchik WD. Animal models of chronic graft-versus-host disease.
In: Vogelsang G, Pavletic S, editors. Chronic Graft-Versus-Host Disease. Cambridge, UK:
Cambridge University Press; 2009. p. 31-45.
[148] Van Rooijen N. The liposome-mediated macrophage 'suicide' technique. J Immunol
Methods 1989;124(1):1-6.
[149] Zhang Y, Shlomchik WD, Joe G, Louboutin JP, Zhu J, Rivera A, et al. APCs in the liver
and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-
host disease. J Immunol 2002;169(12):7111-8.
[150] Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, et al. Targeted disrup-
tion of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis,
mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies,
and reproductive defects. Blood 2002;99(1):111-20.
[151] Ginhoux F, Liu K, Helft J, Bogunovic M, Greter M, Hashimoto D, et al. The origin and
development of nonlymphoid tissue CD103+ DCs. J Exp Med 2009;206(13):3115-30.
[152] MacDonald KPA, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, et al. An
antibody against the colony stimulating factor 1 receptor depletes the resident subset
of monocytes and tissue- and tumor-associated macrophages but does not inhibit
inflammation. Blood 2010;116(19):3955-63.
194
Search WWH ::
Custom Search